Objective: To investigate the postoperative analgesic effects of parecoxib for uvulopalatopharyngoplasty (UPPP). Methods: Patients with obstructive sleep apnoea syndrome who underwent UPPP were randomly divided into two groups. In group A, the incision-local block was performed with 5 ml of 0.5% ropivacaine injected subcutaneously before the end of surgery, then 20 ml of physiological saline was injected intravenously every 12 h for 2 days. In group B, in addition to the incision-local block, 40 mg parecoxib was injected intravenously 30 min before the end of UPPP and 40 mg parecoxib was injected intravenously every 12 h for 2 days. Postoperative pain was measured using a visual analogue scale (VAS). Adverse reactions were recorded. Results: A total of 40 patients were randomized (n ¼ 20 per group). Under resting conditions, the mean AE SD VAS pain scores were significantly higher in group A compared with group B at 24 h and 48 h after UPPP (24 h 4.0 AE 0.8 versus 2.6 AE 0.6; 48 h 3.8 AE 0.7 versus 2.4 AE 0.5; respectively). Under swallowing conditions, the mean AE SD VAS pain scores were significantly higher in group A compared with group B at 8 h, 24 h and 48 h after UPPP. Postoperative adverse reactions were similar in the two groups. Conclusion: Intravenous parecoxib combined with incision-local ropivacaine provided effective postoperative analgesia for patients with obstructive sleep apnoea syndrome, undergoing UPPP.
Introduction
Analgesia following uvulopalatopharyngoplasty (UPPP) is a difficult problem in patients with obstructive sleep apnoea syndrome. Opioid-based analgesic protocols are usually used for postoperative analgesia for other diseases, 1,2 but because opioids can easily lead to respiratory depression, their use can be life threatening in patients with obstructive sleep apnoea syndrome. 3, 4 Therefore, it is necessary to find a safe postoperative analgesic method for these patients.
Parecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, may be a useful postoperative analgesia for patients with obstructive sleep apnoea syndrome because it provides effective analgesia but does not induce respiratory depression. 5 The present study investigated the analgesic effects of parecoxib in patients with obstructive sleep apnoea syndrome undergoing UPPP.
Patients and methods

Patient population
The study recruited patients with obstructive sleep apnoea syndrome who underwent UPPP under general anaesthesia at the Department of Anaesthesiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China, between June 2011 and May 2012. Inclusion criteria were American Society of Anesthesiologists physical status classification II and no requirement for ventilatory support. All patients received postoperative analgesia. All patients were aged 35-60 years. Exclusion criteria included: (i) preoperative blood pressure >160/100 mmHg; (ii) severe arrhythmias including frequent ventricular premature contractions, paroxysmal ventricular tachycardia, auricular fibrillation or precordial distress; (iii) postoperative ventilatory support; (iv) second surgery caused by postoperative bleeding.
All study methods were approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. All patients enrolled into the study gave their written informed consent to participate.
Study design and data collection
Patients were randomly divided into groups A and B, according to a computergenerated randomization schedule. In group A, the incision-local block was performed with 5 ml of 0.5% ropivacaine injected subcutaneously before the end of surgery, then 20 ml of physiological saline was injected intravenously every 12 h for 2 days. In group B, in addition to the incision-local block with ropivacaine, 40 mg parecoxib (Pharmacia and Upjohn, Kalamazoo, MI, USA) was injected intravenously 30 min before the end of UPPP, then 40 mg parecoxib was injected intravenously every 12 h for 2 days.
The following evaluations were undertaken for each patient: (i) intraoperative and postoperative electrocardiogram, noninvasive blood pressure and blood oxygen saturation (SaO 2 ); (ii) time taken to awaken from anaesthesia; (iii) visual analogue scale (VAS) pain scores (0 cm representing no pain; 10 cm representing worst pain imaginable), 30 min after return to consciousness and at 2 h, 8 h, 24 h and 48 h after UPPP; (iv) incidence of postoperative complications such as bleeding, nausea, vomiting, upper respiratory tract obstruction, frequency of SaO 2 <90%, the frequency of serious cardiac arrhythmias including heart rate <50 beats per min, heart rate >100 beats per min or premature ventricular contraction >5 times per min.
Anaesthetic procedure
Nasotracheal intubation was performed using topical anaesthesia in all patients. The endotracheal tube was fixed in place and used to administer 100% oxygen. Within 2 min, 2 mg/kg propofol, 0.2 mg/kg cisatracurium and 3 mg/kg fentanyl were intravenously injected. When patients fell asleep, assisted mechanical ventilation was performed. Inhalation of 2-3% sevoflurane (or continuous infusion of propofol at 4-6 mg/kg per h), continuous infusion of remifentanil at 0.2 mg/kg per min and intermittent intravenous injections of 10-20 mg atracurium were used for maintenance of anaesthesia. Patients were maintained in the supine position during the operation. After full exposure of the pharyngeal cavity with a mouth gag, the bilateral tonsils were first removed, then the redundant fat in the space between the veli palatine and the uvula root was removed. While ensuring the apposition suturing of the palatoglossal arch and the presence of a certain level of tensile force, the redundant mucosa around the palatopharyngeal arch was removed as extensively as possible, then the mucous membrane was sutured to reconstruct the pharyngeal cavity. These surgical procedures were undertaken by the same surgeons in all patients (Drs Ying Wang and Ming-Shuan Lv, Department of Otolaryngology, First Affiliated Hospital of Zhengzhou University). The same two surgeons administered all study drugs to the patients in both groups.
Pain assessments and follow-up examinations were performed by the investigators (G-L.X. and Q-J.C.) who were blinded to the use of parecoxib in group B.
Statistical analyses
All statistical analyses were performed using the SPSS Õ software package, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows Õ . Data were presented as mean AE SD. Independent t-test was used to compare the mean demographic and VAS pain scores between the two groups. The comparison of the rates of adverse reactions between the two groups was performed with 2 -test. A P-value < 0.05 was considered statistically significant.
Results
A total of 40 patients (age range 35-60 years) were randomized to groups A and B (each group with 20 patients). Their demographic and surgical characteristics are presented in Table 1 . There were no significant differences in age, body weight, height, duration of surgery and the time taken to awaken from anaesthesia between the two groups.
In terms of the resting VAS pain scores, patients in group B had significantly lower scores compared with those in group A at 24 h and 48 h after UPPP (P < 0.05 for both comparisons; Table 2 ). In terms of the Table 2 ). There were no between-group differences in incidence of adverse reactions (Table 3 ).
Discussion
Obstructive sleep apnoea syndrome, which is a common sleep disorder, is caused by partial or complete upper respiratory tract obstruction and is characterized by >10 s of respiratory arrest in sleep. The incidence of mild-to-severe obstructive sleep apnoea syndrome is >20% in people aged 30-70 years. 6 The incidence of postoperative complications and mortality markedly increase, even in patients with those with mild disease. 7, 8 UPPP is a common method for the treatment of moderate-to-severe obstructive sleep apnoea syndrome, 9 but wound-related pain is severe following UPPP, making adequate postoperative analgesia necessary. 10 Traditional postoperative analgesia is most frequently performed with opioids and although the analgesic effects of such agents are well known, their potential adverse reactions (such as excessive sedation and respiratory depression) limit their application in postoperative UPPP analgesia. 11 Any postoperative analgesics used for patients with obstructive sleep apnoea syndrome should not produce excessive sedation and respiratory depression because this might aggravate respiratory tract obstruction, which could even lead to suffocation and death. Therefore, the American Society of Anesthesiologists recommends local anaesthesia for postoperative UPPP analgesia in order to avoid the adverse effects caused by the systemic use of opioids. 10 In our current study, the postoperative UPPP analgesic effects were compared between local anaesthesia alone and local anaesthesia combined with intravenous parecoxib, in patients with obstructive sleep apnoea syndrome undergoing UPPP. The current results demonstrated that compared with local anaesthesia alone, local anaesthesia combined with intravenous parecoxib provided significantly better relief of resting pain at 24 h and 48 h after UPPP and of swallowing pain at 8 h, 24 h and 48 h after UPPP. The analgesic effects of local anaesthesia with ropivacaine only lasted up to 8 h for resting pain, as demonstrated by significantly higher resting VAS scores in those who received local anaesthesia alone (group A) compared with those who received local anaesthesia combined with intravenous parecoxib (group B) at 24 h and 48 h after UPPP. These findings suggest that local anaesthesia combined with intravenous parecoxib could improve postoperative analgesia in patients with obstructive sleep apnoea syndrome undergoing UPPP. Parecoxib, a selective COX-2 inhibitor, can inhibit the production of both peripheral and central COX-2, and reduce the synthesis of both peripheral and central prostaglandin, thereby exerting dual analgesic effects. 12 Parecoxib has a rapid onset and long duration of action. 13 If a single intravenous injection of 40 mg of parecoxib is given, the analgesic effects occur within 7-13 min, analgesia reaches the maximum effect 2 h after administration and the analgesia can last for more than 6 h. 13 The analgesic effects of a single intravenous injection of 40 mg parecoxib are better than a single intravenous injection of 4 mg morphine. 14 The findings of our current study suggest that local anaesthesia combined with intravenous parecoxib can: (i) compensate for the short analgesic effect of local anaesthetic alone; (ii) avoid excessive sedation and respiratory depression caused by systemic opioids; (iii) provide well tolerated postoperative analgesia in patients with obstructive sleep apnoea syndrome undergoing UPPP.
In conclusion, the use of the local anaesthetic ropivacaine combined with intravenous parecoxib provided a well tolerated and effective postoperative analgesic strategy for patients with obstructive sleep apnoea syndrome undergoing UPPP, because it provided significantly better resting pain relief at 24 h and 48 h after UPPP and significantly better swallowing pain relief at 8 h, 24 h and 48 h after UPPP, compared with local anaesthetic alone.
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